UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vertex Pharmaceuticals Incorporated Registrant's telephone number, including area code (617) 341-6100 Securities registered pursuant to Se ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Q4 2022 Earnings Conference Call February 7, 2023 4:30 PM ET Company Participants Susie Lisa - Senior Vice President, Investor Relations Reshma Kewalramani - Chief Executive Officer and President Stuart Arbuckle - Chief Operating Officer Charlie Wagner - Chief Financial Officer Conference Call Participants Salveen Richter - Goldman Sachs Geoff Meacham - Bank of America Phil Nadeau - Cowen Liisa Bayko - Evercore ISI David Risinger - SVB Robyn Karnauskas - Tru ...

FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS ©2023 Vertex Pharmaceuticals Incorporated VERTEX FEBRUARY 7, 2023 AGENDA Introduction Susie Lisa, CFA, Senior Vice President, Investor Relations CEO Perspective and Pipeline Update Reshma Kewalramani, M.D., Chief Executive Officer and President Commercial Update Stuart Arbuckle, Executive Vice President and Chief Operating Officer Financial Results Charlie Wagner, Executive Vice President and Chief Financial Officer ©2023 Vertex Pharmaceuticals Incorporate ...

VERTEX THE SCIENCE of POSSIBILITY J.P. MORGAN HEALTHCARE CONFERENCE RESHMA KEWALRAMANI, M.D. CEO AND PRESIDENT JANUARY 2023 ©2023 Vertex Pharmaceuticals Incorporated global.vrtx.com | --- | --- | --- | --- | --- | |--------------------------------------------|-------|----------|-------|-------| | | | | | | | SAFE HARBOR STATEMENT & NONGAAP FINANCIAL | | | | | | | | MEASURES | | | | | | | | | | | | | | | | ©2023 Vertex Pharmaceuticals Incorporated | | | | | This presentation contains forward-looking statemen ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) 41st Annual J.P. Morgan Healthcare Conference Call January 9, 2023 11:15 AM ET Company Participants Reshma Kewalramani - Chief Executive Officer and President Charlie Wagner - Chief Financial Officer Stuart Arbuckle - Chief Operating Officer David Altshuler - Executive Vice President, Global Research, and Chief Scientific Officer Conference Call Participants Jessica Fye - J.P. Morgan Jessica Fye Great. Good morning, everyone. Welcome. I'm Jessica Fye. I'm a ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 ____________________________________________ Vertex Ph ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED JUNE 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 ____________________________________________ Vertex Pharmac ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 ____________________________________________ Vertex Pharma ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 Vertex Pharmaceuticals Incorporated (Exact name of registrant as specified in its charter) Massachusetts (State or other jurisdiction of i ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ________________________________________________________ FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission file number 000-19319 ____________________________________________ Vertex Ph ...